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Transthoracic synchronized direct current discharge or car-
dioversion was introduced nearly 25 years ago to restore
sinus rhythm in patients with diverse tachyarrhythmias (I).
This simple, expeditious and nearly complication-freemethod
has withstood the test of time.
The likelihood of serious adverse reactions is related
more to the underlying mechanism being treated than to the
electrical discharge itself. Systemic and pulmonary embo-
lism are among the more serious complications and are
encountered in about I% of those who undergo cardiover-
sion of atrial fibrillation without anticoagulant drug pro-
phylaxis. In rare instances, cardioversion induces or aggra-
vates preexisting pulmonary congestion. Immediately after
the procedure, arrhythmias are common, usually consisting
of atrial, junctional or ventricular ectopic beats that disap-
pear within several minutes. Malignant arrhythmias are the
result of improper synchronization or excessive electrical
energy, generally in patients with severe degrees of myo-
cardial dysfunction.
Shortly after the introduction of cardioversion, the report
of two deaths (2,3) raised the concern that the digitalized
patient may be susceptible to electrical shock-induced ar-
rhythmias. Both patients were overdigitalized and the elec-
trical discharge provoked irreversible ventricular fibrilla-
tion. Animal experiments (4) have confirmed that digitalization
enhances the arrhythmogenic effect of transthoracic shock.
In normal dogs digitalized to near toxicity, the median en-
ergy for inducing ventricular tachycardia is lowered from
400 to 0.2 J, a 2,OOO-fold reduction. The arrhythmia pro-
voked by electrical discharge in the digitalized heart is iden-
tical in configuration and rate to that resulting from excess
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digitalis in the absence of electric shock. When the elec-
trical threshold is tested during incremental digitalization,
increased susceptibility to ventricular tachycardia requires
administration of approximately 85% of a toxic dose of
ouabain.
In the digitalized heart, pacemaker stimuli to either right
or left ventricular endocardium elicit repetitive ventricular
responses with as little as 1 to 2 J-LJ (5). In the normal heart,
such responses are difficult to induce except with extraor-
dinarily high currents of about 5 to 6 J; this represents a
difference of six orders of magnitude in energy level. With
advancing degrees of digitalization, the repetitive response
increases in the number of successive cycles, resulting ul-
timately in sustained ventricular tachycardia. The phenom-
enon of repetitive ventricular response has been elicited in
diverse mammalian species as well as in human beings (6).
There can be little doubt that digitalis drugs sensitize the
heart to electrical shock-induced ventricular arrhythmias,
Clinicians accept this fact, but have been hard pressed
to identify the subject at risk. The practice has been to
discontinue digitalis drugs for I day or more before car-
dioversion. This approach has a disadvantage for the patient
who is dependent on digitalis for ventricular rate control.
Stopping digoxin for I day or more unduly accelerates the
heart rate, especially after initiation of quinidine therapy.
If cardiac reserve already is compromised, discontinuation
of glycosides may provoke decompensation, impede res-
toration of sinus rhythm and, even if cardioversion is im-
mediately successful, the normal mechanism may not persist.
Role of the Digoxin Blood Level
The study of Mann et a1. (7) in this issue is, therefore,
of some interest. Their thesis is that if the digoxin blood
level is in a therapeutic range (0.5 to 1.9 ng/ml), cardiov-
ersion does not provoke ventricular ectopic activity even
after high levels of applied shock. This confirms the earlier
report of Ditchey and Karliner (8), who found no increase
in ventricular ectopic activity among 21 patients with serum
digoxin levels ranging from 0.1 to 3.0 nglml (mean 1.6).
Of note was that among their eight patients with modestly
elevated serum digoxin concentrations «2.0 ng/ml), ven-
tricular premature beats remained unchanged in pre- and
post-shock recordings. The study by Ditchey and Karliner
may have been confounded by the fact that their patients,
unlike those of Mann et al., were receiving quinidine. How-
ever, quinidine pretreatment has not been shown to protect
against postcardioversion ventricular arrhythmias (9).
A single variable such as the serum digoxin concentration
may not predict safety from postcardioversion arrhythmias.
Indeed, in digitalized patients, no correlation exists between
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cation when assessed by means of the ultrarapid-acting car-
diac aglycone, acetylstrophanthidin (10). The serum digoxin
concentration does not provide information concerning
myocardial sensitivity to glycoside-provoked ventricular ar-
rhythmias. Cardiac sensitivity is determined by a multi-
plicity of variables, including myocardial functional im-
pairment, presence and extent of ischemia, age of the patient,
serum potassium and magnesium concentrations, the state
of adrenergic tone and a host of other factors. It is, therefore,
unlikely that the serum digoxin level in the individual patient
will predict development of cardioversion-induced arrhyth-
mias. One would have to concur with the conclusion of
Ditchey and Karliner "that within reasonable limits, serum
digoxin levels are of little value in predicting the risk of
electrical cardioversion in patients apparently without dig-
italis toxicity."
Clinical Recommendations
How then is one to deal with the digitalized patient with
atrial fibrillation who is to undergo cardioversion? Twenty
years ago, it was already known that the patient who de-
veloped malignant ventricular arrhythmias after cardiover-
sion presented with findings suggestive of digitalis over-
dosage before cardioversion (11). Now we know that the
patient with atrial fibrillation who exhibits paroxysms of
regularized rhythm, bradycardia or early junctional or idio-
ventricular escape with carotid sinus massage has a 50%
chance of developing ventricular arrhythmias after cardio-
version. In such cases, one can either delay cardioversion
or titrate the energy of the discharge. The latter procedure
assures the safety of cardioversion. The starting energy is
adjusted to the anticipated likelihood of overdigitalization.
When this possibility is high, one begins with 10 J and
progresses stepwise to 50, 100, 200 J and so forth (12). If
ectopic activity emerges that can be subdued with lidocaine,
it is safe to proceed to the next level of energy. Attention
to these methodologic details, in combination with a relaxed
patient who is reassured about the safety of the procedure,
diminishes the likelihood of serious complications. Adher-
ing to these principles, we have encountered no major un-
toward effects in more than 1,000 cardioversions for chronic
atrial fibrillation.
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